FON-2021-1367.docx (19.65 kB)

fon-2021-1367 – First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population

dataset

posted on 2022-05-19, 08:05 authored by Alycia Hatashima, Matthew J Arango, Joshua Reardon, Tracelyn Freeman, Terence Williams, Eric M McLaughlin, Laith Abushahin

Table S1 Hazard Ratios with and without Inverse Probability Weights

Table S2 Multivariate Analysis: Prognostic Factors for Overall Survival

Funding

Ohio State University Center for Clinical and Translational Science grant support (National Center for Advancing Translational Sciences, Grant UL1TR001070)

History

Usage metrics

Future Oncology

Keywords

FOLFIRINOX gemcitabine metastatic pancreatic adenocarcinoma nab-paclitaxel real-world evidence survival

Licence

CC BY-NC-ND 4.0